<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04784182</url>
  </required_header>
  <id_info>
    <org_study_id>21-110</org_study_id>
    <nct_id>NCT04784182</nct_id>
  </id_info>
  <brief_title>Anti-anxiety Biotics for Breast Cancer Survivors</brief_title>
  <acronym>ABBCS</acronym>
  <official_title>Synbiotic Supplementation to Reduce Anxiety Symptoms in Female Breast Cancer Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Auburn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Alabama at Birmingham - Center for Clinical and Translational Science</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Auburn University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cancer survivors experience more rapid declines in health-related quality of life which&#xD;
      include physical and psychological comorbidities, the latter of which may be subclinical and&#xD;
      often overlooked by primary care providers. Recently, the gut-brain axis (GBA) has been&#xD;
      identified as a therapeutic target to improve host health. The GBA is greatly influenced by&#xD;
      the composition of the gut microbiome, as microbial metabolites directly influence the&#xD;
      central nervous system. Thus, prebiotics, probiotics, and synbiotics (a combination of pre-&#xD;
      and probiotics) have emerged as a possible approach to treating anxiety symptoms. Preclinical&#xD;
      studies suggest efficacy of synbiotics, while pre- and probiotics have only been studied in&#xD;
      isolation in humans.&#xD;
&#xD;
      This is a double-blind, placebo-controlled clinical trial in which female breast cancer&#xD;
      survivors experiencing moderate to severe anxiety symptoms will be randomized to daily&#xD;
      consumption of the synbiotic supplement or placebo. The previously validated Generalized&#xD;
      Anxiety Disorder-7 (GAD-7) will be used to assess anxiety symptom severity at study screening&#xD;
      and at each time point. The primary outcome of this study is feasibility, measured by&#xD;
      accrual, adherence, retention, and adverse effects. Secondary outcomes relate to reduction of&#xD;
      anxiety symptoms and other physiological changes. No study has investigated the mediating&#xD;
      effects of gut microbiota and inflammatory markers on the ability of synbiotics to reduce&#xD;
      anxiety symptoms. Thus, at each timepoint, phlebotomy will be conducted to determine serum&#xD;
      levels of inflammatory cytokines and stool samples will be collected to determine alpha- and&#xD;
      beta-diversity of the fecal microbiome as well as relative abundance of target genera.&#xD;
      Hypothesis: this placebo-controlled study will be feasible and synbiotic treatment will&#xD;
      result in a significant reduction in anxiety symptoms and inflammatory markers, which may be&#xD;
      moderated by changes in the microbiome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 20, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Placebo controlled randomized controlled trial</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>One study staff member will be responsible for randomization and allocation of intervention supplement or placebo, which will be appear to be identical</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility - accrual</measure>
    <time_frame>6 months</time_frame>
    <description>Accrue 48 participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility - retention</measure>
    <time_frame>6 weeks</time_frame>
    <description>Retain 85% of randomized participants for duration of study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility - adherence</measure>
    <time_frame>4 weeks</time_frame>
    <description>80% of participants consuming pills on 90% of intervention days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anxiety symptoms</measure>
    <time_frame>4 weeks</time_frame>
    <description>Decrease in Generalized Anxiety Disorder-7 score, which ranges from 0 (no anxiety) to 21 (severe anxiety).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serotonin</measure>
    <time_frame>4 weeks</time_frame>
    <description>Serum 5-hydroxytryptamine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory marker - TNF-alpha</measure>
    <time_frame>4 weeks</time_frame>
    <description>Serum Tumor Necrosis Factor-alpha</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory marker - LBP</measure>
    <time_frame>4 weeks</time_frame>
    <description>Serum Lipopolysaccharide Binding Protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory marker - IL-6</measure>
    <time_frame>4 weeks</time_frame>
    <description>Serum Interleukin-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal microbiome composition</measure>
    <time_frame>4 weeks</time_frame>
    <description>16s changes in microbiota alpha diversity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Anxiety Generalized</condition>
  <condition>Breast Cancer Female</condition>
  <arm_group>
    <arm_group_label>Synbiotic supplement group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily consumption of pills containing prebiotics and probiotics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily consumption of pills containing maltodextrin</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>probiotic plus prebiotic supplement</intervention_name>
    <description>Daily consumption of probiotic containing at least 5 billion CFU per day total bacteria including Lactobacillus helveticus and Bifidobacterium longum and prebiotic containing 4 grams of fructooligosaccharides (FOS)</description>
    <arm_group_label>Synbiotic supplement group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Daily consumption of visually similar placebo pills</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Female breast cancer survivors who:&#xD;
&#xD;
          1. are 50-75 years of age&#xD;
&#xD;
          2. have completed primary treatment&#xD;
&#xD;
          3. currently experience clinical anxiety symptoms determined by the 7 item Generalized&#xD;
             Anxiety Disorder screener (GAD-7; eligibility requires a total score of 5 or higher on&#xD;
             the 21 point scale)&#xD;
&#xD;
          4. agree not to change dietary supplements throughout the course of the study&#xD;
&#xD;
          5. are willing to comply with daily supplement regimen&#xD;
&#xD;
          6. are able to speak and read English.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. use of any of the following drugs within the last 4 weeks (unless indefinitely&#xD;
             prescribed): systemic antibiotics, corticosteroids, immunosuppressive agents, or&#xD;
             commercial probiotics&#xD;
&#xD;
          2. changes in treatment for anxiety symptoms (i.e. initiation of Cognitive Behavior&#xD;
             Therapy (CBT) within the last four weeks&#xD;
&#xD;
          3. current use (within 12 weeks) of anxiolytic medications.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew D Frugé, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Auburn University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew D Frugé, PhD</last_name>
    <phone>3348443271</phone>
    <email>fruge@auburn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristen S Smith, MS</last_name>
    <email>kss0034@auburn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Auburn University</name>
      <address>
        <city>Auburn</city>
        <state>Alabama</state>
        <zip>36849</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew D Frugé, PhD</last_name>
      <phone>334-844-3271</phone>
      <email>fruge@auburn.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://aub.ie/survivor</url>
    <description>Study website</description>
  </link>
  <reference>
    <citation>Smith KS, Greene MW, Babu JR, Frugé AD. Psychobiotics as treatment for anxiety, depression, and related symptoms: a systematic review. Nutr Neurosci. 2019 Dec 20:1-15. doi: 10.1080/1028415X.2019.1701220. [Epub ahead of print]</citation>
    <PMID>31858898</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Auburn University</investigator_affiliation>
    <investigator_full_name>Andrew Fruge</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

